|
Borderline Personality Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Various levels of GPC1-positive and GP2/GPC1-positive EVs were detected in PDAC patients but were not significantly higher than benign pancreatic disease (BPD) patients.
|
30800217 |
2019 |
|
Bronchopulmonary Dysplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Various levels of GPC1-positive and GP2/GPC1-positive EVs were detected in PDAC patients but were not significantly higher than benign pancreatic disease (BPD) patients.
|
30800217 |
2019 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Glypican-1 provides the mechanical linkage from HS (the flow sensor) to the SN12L1 cell where mechanotransduction leading to the enhancement of migration (metastasis) occurs.
|
31256115 |
2019 |
|
Schizophrenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest dysregulation of ER-associated GPI-AP protein processing, with impacts on post-translational modifications of proteins previously implicated in schizophrenia such as NCAM and GPC1.
|
30664618 |
2019 |
|
Hereditary hemochromatosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Knockdown of Gpc1 reduced Hh pathway activity, and phenocopied the effect of miR-324-5p on osteogenesis, indicating that miR-324-5p regulates Hh signalling in mouse via direct targeting of Gpc1.
|
30193893 |
2019 |
|
PACHYONYCHIA CONGENITA 3
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further, GPC-1 inhibition increased PC-3 tumor size in NCr nude mice xenografts.
|
31391540 |
2019 |
|
Resectable Pancreatic Ductal Adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma.
|
31400579 |
2019 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
The mean H-score for glypican-1 of mesothelioma (134 ± 59, mean ± SD) was not significantly different from that for pulmonary adenocarcinoma (156 ± 60; P = 0.21).
|
29785020 |
2018 |
|
Squamous cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Glypican-1 (GPC1) is highly expressed in solid tumors, especially squamous cell carcinomas (SCCs), and is thought to be associated with disease progression.
|
29055044 |
2018 |
|
Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
According the Kaplan-Meier curves, HS accumulation in glioma cells was associated with low relapse-free survival (RS) of the GBM patients (p < 0.05) and was likely to be due to the increased transcriptional activity of HSPG core proteins (syndecan-1, 2-3 fold; glypican-1, 2,5 fold; perlecan/HSPG2, 13-14 fold).
|
29322326 |
2018 |
|
Mesothelioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, glypican-1 IHC does not differentiate mesothelioma from pulmonary adenocarcinoma.
|
29785020 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Glypican-1 expression showed 100 sensitivity, 97% specificity, and a 98% accuracy rate to differentiate epithelioid mesothelioma from lung adenocarcinoma.
|
29327712 |
2018 |
|
Cholangiocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Serum GPC1 levels in PDAC were different from those in gallbladder carcinoma (P < 0.001), colorectal carcinoma (P < 0.001), gastric carcinoma (P < 0.001), and prostate cancer (P < 0.001), but not hepatocellular carcinoma (P = 0.395) and cholangiocarcinoma (P = 0.724).
|
30358133 |
2018 |
|
Gallbladder Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Serum GPC1 levels in PDAC were different from those in gallbladder carcinoma (P < 0.001), colorectal carcinoma (P < 0.001), gastric carcinoma (P < 0.001), and prostate cancer (P < 0.001), but not hepatocellular carcinoma (P = 0.395) and cholangiocarcinoma (P = 0.724).
|
30358133 |
2018 |
|
Adenocarcinoma of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
Glypican-1 (GPC1) in exosomes has been identified as an early diagnostic biomarker for pancreatic adenocarcinoma.
|
29963198 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The use of MIL-38 to detect GPC-1 by IFA discriminated between prostate cancer and BPH urine specimens with a sensitivity and specificity of 71% and 76%, respectively.
|
29672570 |
2018 |
|
cervical cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
We explored the use of a GPC1-targeted antibody-drug conjugate (ADC) as a novel treatment for uterine cervical cancer.
|
29055044 |
2018 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
The clinical significance of circulating GPC1 positive exosomes and its regulative miRNAs in colon cancer patients.
|
29254156 |
2017 |
|
Craniosynostosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Glypican 1 (GPC1) and glypican 3 (GPC3) are bone co-regulators that act downstream in many of the signalling pathways associated with craniosynostosis.
|
28426184 |
2017 |
|
Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
GPC-1 expression was examined by immunohistochemistry in 53 patients with GBM who received radiotherapy and temozolomide treatment.
|
28602885 |
2017 |
|
Pancreatitis, Chronic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Thus, our exosomal miR signature is superior to exosomal GPC1 or plasma CA 19-9 levels in establishing a diagnosis of PDAC and differentiating between PDAC and CP.
|
28232049 |
2017 |
|
Stage III Colon Cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that high levels of circulating GPC1 positive exosomes before and after surgery as well as low circulating miR-96-5p and miR-149 before surgery indicated a severe clinical status and poor prognosis in stage III colon cancer patients.
|
29254156 |
2017 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The clinical significance of circulating GPC1 positive exosomes and its regulative miRNAs in colon cancer patients.
|
29254156 |
2017 |
|
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
α3 Chains of type V collagen regulate breast tumour growth via glypican-1.
|
28102194 |
2017 |
|
Stage III Colon Cancer AJCC v7
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that high levels of circulating GPC1 positive exosomes before and after surgery as well as low circulating miR-96-5p and miR-149 before surgery indicated a severe clinical status and poor prognosis in stage III colon cancer patients.
|
29254156 |
2017 |